# Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes

Source: https://nuclide.cc/ideas/idea-reg-regional-radiopharmacy-hubs/  
Nuclide record `idea-reg-regional-radiopharmacy-hubs` (Idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Radioactive cancer drugs decay while they travel and get stuck at borders. Regional production and simpler transport rules would get more doses to patients on time.

## Summary

Radioligand therapies are often labelled centrally and shipped internationally, losing activity to decay and to customs delays; dangerous goods rules differ by country and carrier. The proposal is a network of regional GMP radiopharmacies (one per few million population) receiving bulk isotope and cold kits, labelling on demand, and delivering same-day, combined with an IAEA-brokered harmonisation of Class 7 transport paperwork and pre-clearance for medical isotopes at major airports.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Regional labelling and pre-clearance reduce the share of radioligand doses cancelled or postponed for supply reasons from roughly 5-10% to below 1% and reduce shipped activity per delivered dose by at least a quarter.
- Rationale: Nuclear medicine already runs this way for diagnostic isotopes (technetium generators, fluorine-18 cyclotron networks). Therapeutic isotopes have longer half-lives but far higher per-dose value, so the economics of regional hubs are favourable.
- Proposed test: Pilot two regional hubs in a large country and measure dose cancellation rates, shipped activity per dose and cost per dose against central supply over one year.
- Maturity: early-clinical
- Actor: industry

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- technologies: [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- drugs: [Lutetium-177 dotatate](https://nuclide.cc/drugs/lutathera/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- terms: [Theranostics](https://nuclide.cc/terms/theranostics/)
- bottlenecks: [Cold chain and time-critical logistics](https://nuclide.cc/bottlenecks/b-cold-chain-logistics/), [Manufacturing cost and time for living and radioactive medicines](https://nuclide.cc/bottlenecks/b-manufacturing-cell-therapy/)
- ideas: [In-house hospital radiopharmacy compounding to cut dose waste](https://nuclide.cc/ideas/idea-regional-radiopharmacy-network/)
- roadmaps: [Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium](https://nuclide.cc/roadmaps/isotope-supply-roadmap/)

---
JSON: https://nuclide.cc/api/v1/entities/idea-reg-regional-radiopharmacy-hubs.json